カテゴリ： Market Research Future, 世界, 医療/バイオ

世界の血栓治療市場（～2030）

■ 英語タイトル：Global Thrombus Treatment Market Forecast to 2030
	■ 発行会社/調査会社：Market Research Future ■ 商品コード：MRF23JNE030 ■ 発行日：2023年6月 ■ 調査対象地域：グローバル ■ 産業分野：医療 ■ ページ数：128 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール

■ 販売価格オプション（消費税別）

Single User（印刷不可、Online Access）	USD4,950 ⇒換算￥752,400	見積依頼/購入/質問フォーム
Enterprisewide Price（印刷可）	USD7,250 ⇒換算￥1,102,000	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Research Future社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[世界の血栓治療市場（～2030）]についてメールでお問い合わせはこちら

*** レポート概要（サマリー）***

Market Research Future社は、世界の血栓治療市場が予測期間中に年平均成長率6.84％を記録すると予測しています。本書では、血栓治療の世界市場の現状について多面的に調査・分析し、イントロダクション、調査手法、市場インサイト、市場動向、市場要因分析、種類別（心房血栓、静脈血栓）分析、治療別（医学療法、手術、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、その他地域）分析、競争状況、企業情報など、以下の構成でまとめております。なお、当市場の主要企業には、Teva Pharmaceutical Industries Ltd. (Israel)、AngioDynamics Inc. (US)、Bristol-Myers Squibb Company (US)、Pfizer Inc. (US)、Johnson & Johnson Services Inc. (US)、Sanofi S.A. (France)、Daiichi Sankyo Company、Limited (Tokyo)、Boehringer Ingelheim International GmbH (Germany)、Aspen Pharmacare Holdings Limited (US)などが含まれています。
・エグゼクティブサマリー
・イントロダクション
・調査手法
・市場動向
・市場要因分析
・世界の血栓治療市場規模：種類別
　 - 心房血栓の市場規模
　 - 静脈血栓の市場規模
・世界の血栓治療市場規模：治療別
　 - 医学療法における市場規模
　 - 手術における市場規模
　 - その他治療における市場規模
・世界の血栓治療市場規模：地域別
　 - 北米の血栓治療市場規模
　 - ヨーロッパの血栓治療市場規模
　- アジア太平洋の血栓治療市場規模
　- その他地域の血栓治療市場規模
・競争状況
・企業情報

血栓治療の2030年までの市場予測

市場概要：
血栓治療市場は、予測期間中に6.84%の堅実なCAGRを記録すると予測されています。市場発展に影響を与えている要素は、市場発展を支えている傷害ケースの割合の上昇と定常的な生活様式の受容の高まりです。
傷害は、下限における血栓の配置のための最も広く認識される理由の一つとして見られています。静脈が損傷を受けると、周囲の血液が濃くなり、凝固が起こります。その後、傷害のために静脈の害は、血栓の開発を引き起こす可能性があります。傷害のケースの拡大数は、特に通りの災難は、血栓治療の普及拡大を促しています。2022年6月のWHOによると、世界中で約 130 万人が路上事故で命を落としています。これは、1990年頃から33.4％拡大し、2019年に新たに登録された骨折症例は世界で178百万件でした。強烈な長距離休憩による副作用の絶対的な蔓延は、1990年頃から67.5％の増加で、XX年には455百万に達していました。骨折は脳卒中の典型的な原因の一つです。その結果、傷害ケースの発生が増加し、血栓治療の市場の関心を牽引しています。

市場区分：
心房血栓と静脈血栓は、それぞれ血栓治療の2つの市場セグメントです。右心房血栓と左心房血栓は心房血栓から形成されます。
血栓治療市場のデータは、薬物療法、手術、その他などの治療カテゴリーに分類されています。血栓溶解薬、抗血小板薬、抗凝固薬は薬物療法の構成要素です。

地域分析：
北米は最大の市場シェアを占めており、医療基盤の構築、保護された強力な血栓治療を提供するための研究賞、地域の成熟した大規模な人口の発展に起因して、2021年ごとに161.9億米ドルを貢献しています。
欧州の血栓治療市場は、深部静脈卒中の検査と治療が発展していることに起因する2番目に大きな市場シェアを占めており、血栓の問題に関して発展する意識が欧州の市場開発を推進する中心的なポイントとなっています。例えば、Public Community for Biotechnology Data (NCBI)で配信された記事によると、深部静脈卒中(DVT)はヨーロッパにおける医療サービスのトラブルです。
アジア太平洋地域の血栓治療市場は、2022年から2030年まで重要なシェアで発展することになっています。強化された患者プールの存在、深部静脈卒中の普及率の上昇、中国やインドなどの国々で異なる卒中の機会を治療するための治療と薬の利用に関する意識の拡大が、おそらくアジア太平洋地域の市場をサポートするために起こっていることに起因します。また、血栓治療の中国市場は最大の市場シェアを保持し、血栓治療のインド市場はアジア太平洋地域で最も急速に発展している市場です。

主要企業：
この市場調査における主要企業には、Teva Pharmaceutical Industries Ltd. (Israel), AngioDynamics Inc. (US), Bristol-Myers Squibb Company (US), Pfizer Inc. (US), Johnson & Johnson Services Inc. (US), Sanofi S.A. (France), Daiichi Sankyo Company, Limited (Tokyo), Boehringer Ingelheim International GmbH (Germany), Aspen Pharmacare Holdings Limited (US), and Bayer AG (Germany)などが含まれます。

新型コロナウイルスの影響：
弊社では、新型コロナウイルスパンデミックがあらゆる領域のさまざまな業界や業種に与える影響を継続的に追跡しています。当社の調査レポートには、新型コロナウイルスの産業への影響による減少や増加を理解するのに役立ちます。また、貴社が関心をお持ちの市場の需要と供給のギャップを特定するのにも役立ちます。さらに、本レポートは、分析、改正された政府規制、その他多くの有用な洞察を支援します。

*** レポート目次（コンテンツ）***

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING INCIDENCE OF TRAUMA CASES

4.2.2 RISING ADOPTION OF SEDENTARY LIFESTYLE

4.3 RESTRAINTS

4.3.1 RISKS ASSOCIATED WITH THROMBOSIS DRUGS

4.4 OPPORTUNITIES

4.4.1 NEW PRODUCT APPROVALS AND LAUNCHES

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION AND SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE GLOBAL THROMBUS TREATMENT MARKET

5.3.1 IMPACT ON SUPPLY CHAIN

5.3.2 IMPACT ON PRODUCTION

5.3.3 DEMAND-SUPPLY GAP ANALYSIS

5.3.4 IMPACT ON PRICING

5.4 NUMBER OF PROCEDURES FOR PULMONARY EMBOLISM

6 GLOBAL THROMBUS TREATMENT MARKET, BY TYPE

6.1 OVERVIEW

6.2 ATRIAL THROMBUS

6.3 VENOUS THROMBUS

7 GLOBAL THROMBUS TREATMENT MARKET, BY TREATMENT

7.1 OVERVIEW

7.2 MEDICAL THERAPY

7.3 SURGERY

7.4 OTHERS

8 GLOBAL THROMBUS TREATMENT MARKET, BY REGION

8.1 OVERVIEW

8.1.1 NORTH AMERICA

8.1.1.1 US

8.1.1.2 CANADA

8.1.2 EUROPE

8.1.2.1 GERMANY

8.1.2.2 UK

8.1.2.3 FRANCE

8.1.2.4 ITALY

8.1.2.5 SPAIN

8.1.2.6 REST OF EUROPE

8.1.3 ASIA-PACIFIC

8.1.3.1 JAPAN

8.1.3.2 CHINA

8.1.3.3 INDIA

8.1.3.4 AUSTRALIA

8.1.3.5 SOUTH KOREA

8.1.3.6 REST OF ASIA-PACIFIC

8.1.4 REST OF THE WORLD

8.1.4.1 MIDDLE EAST

8.1.4.2 AFRICA

8.1.4.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW

9.2 COMPETITIVE BENCHMARKING

9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL THROMBUS TREATMENT MARKET

9.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL THROMBUS TREATMENT MARKET

9.5 KEY DEVELOPMENT ANALYSIS

9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

9.6.1 PRODUCT APPROVALS/PRODUCT LAUNCHES

9.6.2 PARTNERSHIP/COLLABORATION

9.7 MAJOR PLAYERS FINANCIAL MATRIX

9.7.1 SALES (USD MILLION), 2021

9.7.2 R&D (USD MILLION), 2021

10 COMPANY PROFILES

10.1 TEVA PHARMACEUTICAL INDUSTRIES LTD.

10.1.1 COMPANY OVERVIEW

10.1.2 FINANCIAL ANALYSIS

10.1.3 PRODUCTS OFFERED

10.1.4 KEY DEVELOPMENTS

10.1.5 SWOT ANALYSIS

10.1.6 KEY STRATEGIES

10.2 SANOFI

10.2.1 COMPANY OVERVIEW

10.2.2 FINANCIAL OVERVIEW

10.2.3 PRODUCTS OFFERED

10.2.4 KEY DEVELOPMENTS

10.2.5 SWOT ANALYSIS

10.2.6 KEY STRATEGIES

10.3 PFIZER INC.

10.3.1 COMPANY OVERVIEW

10.3.2 FINANCIAL OVERVIEW

10.3.3 PRODUCTS OFFERED

10.3.4 KEY DEVELOPMENTS

10.3.5 SWOT ANALYSIS

10.3.6 KEY STRATEGIES

10.4 BAYER AG

10.4.1 COMPANY OVERVIEW

10.4.2 FINANCIAL OVERVIEW

10.4.3 PRODUCTS OFFERED

10.4.4 KEY DEVELOPMENTS

10.4.5 KEY STRATEGIES

10.5 ANGIODYNAMICS.

10.5.1 COMPANY OVERVIEW

10.5.2 FINANCIAL OVERVIEW

10.5.3 PRODUCTS OFFERED

10.5.4 KEY DEVELOPMENTS

10.5.5 KEY STRATEGIES

10.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

10.6.1 COMPANY OVERVIEW

10.6.2 FINANCIAL OVERVIEW

10.6.3 PRODUCTS OFFERED

10.6.4 KEY DEVELOPMENTS

10.6.5 SWOT ANALYSIS

10.6.6 KEY STRATEGIES

10.7 BRISTOL-MYERS SQUIBB COMPANY

10.7.1 COMPANY OVERVIEW

10.7.2 FINANCIAL OVERVIEW

10.7.3 PRODUCTS OFFERED

10.7.4 KEY DEVELOPMENTS

10.7.5 KEY STRATEGIES

10.8 ASPEN HOLDINGS

10.8.1 COMPANY OVERVIEW

10.8.2 FINANCIAL OVERVIEW

10.8.3 PRODUCTS OFFERED

10.8.4 KEY DEVELOPMENTS

10.8.5 KEY STRATEGIES

10.9 JOHNSON & JOHNSON SERVICES, INC.

10.9.1 COMPANY OVERVIEW

10.9.2 FINANCIAL OVERVIEW

10.9.3 PRODUCTS OFFERED

10.9.4 KEY DEVELOPMENTS

10.9.5 SWOT ANALYSIS

10.9.6 KEY STRATEGIES

10.10 DAIICHI SANKYO COMPANY, LIMITED

10.10.1 COMPANY OVERVIEW

10.10.2 FINANCIAL OVERVIEW

10.10.3 PRODUCTS OFFERED

10.10.4 KEY DEVELOPMENTS

10.10.5 KEY STRATEGIES

11 APPENDIX

11.1 REFERENCES

11.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

TABLE 3 NUMBER OF PROCEDURES FOR PULMONARY EMBOLISM, BY REGION (2021)

TABLE 4 GLOBAL THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 5 GLOBAL THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY REGION, 2018–2030 (USD MILLION)

TABLE 6 GLOBAL THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 7 GLOBAL THROMBUS TREATMENT MARKET, FOR RIGHT ATRIAL THROMBUS, BY REGION, 2018–2030 (USD MILLION)

TABLE 8 GLOBAL THROMBUS TREATMENT MARKET, FOR LEFT ATRIAL THROMBUS, BY REGION, 2018–2030 (USD MILLION)

TABLE 9 GLOBAL THROMBUS TREATMENT MARKET, FOR VENOUS THROMBUS, BY REGION, 2018–2030 (USD MILLION)

TABLE 10 GLOBAL THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 11 GLOBAL THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 12 GLOBAL THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 13 GLOBAL THROMBUS TREATMENT MARKET, FOR ANTIPLATELETS BY TYPE, 2018–2030 (USD MILLION)

TABLE 14 GLOBAL THROMBUS TREATMENT MARKET, FOR ANTICOAGULANTS BY TYPE, 2018–2030 (USD MILLION)

TABLE 15 GLOBAL THROMBUS TREATMENT MARKET, FOR THROMBOLYTICS BY TYPE, 2018–2030 (USD MILLION)

TABLE 16 GLOBAL THROMBUS TREATMENT MARKET, FOR SURGERY, BY REGION, 2018–2030 (USD MILLION)

TABLE 17 GLOBAL THROMBUS TREATMENT MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 18 GLOBAL: THROMBUS TREATMENT MARKET, BY REGION, 2018–2030 (USD MILLION)

TABLE 19 NORTH AMERICA: THROMBUS TREATMENT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 20 NORTH AMERICA: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 21 NORTH AMERICA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030

TABLE 22 NORTH AMERICA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 23 NORTH AMERICA: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 24 US: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 25 US: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 26 US: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030

TABLE 27 US: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 28 CANADA: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 29 CANADA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030

TABLE 30 CANADA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 31 CANADA: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 32 EUROPE: THROMBUS TREATMENT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 33 EUROPE: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 34 EUROPE: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 35 EUROPE: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 36 EUROPE: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 37 GERMANY: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 38 GERMANY: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 39 GERMANY: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 40 GERMANY: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 41 UK: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 42 UK: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 43 UK: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 44 UK: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 45 FRANCE: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 46 FRANCE: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 47 FRANCE: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 48 FRANCE: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 49 ITALY: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 50 ITALY: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 51 ITALY: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 52 ITALY: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 53 SPAIN: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 54 SPAIN: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 55 SPAIN: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 56 SPAIN: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 57 REST OF EUROPE: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 58 REST OF EUROPE: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 59 REST OF EUROPE: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 60 REST OF EUROPE: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 61 ASIA-PACIFIC: THROMBUS TREATMENT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 62 ASIA-PACIFIC: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 63 ASIA-PACIFIC: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030

TABLE 64 ASIA-PACIFIC: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 65 ASIA-PACIFIC: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 66 JAPAN: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 67 JAPAN: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 68 JAPAN: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 69 JAPAN: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 70 CHINA: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 71 CHINA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 72 CHINA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 73 CHINA: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 74 INDIA: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 75 INDIA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 76 INDIA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 77 INDIA: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 78 AUSTRALIA: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 79 AUSTRALIA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 80 AUSTRALIA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 81 AUSTRALIA: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 82 SOUTH KOREA: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 83 SOUTH KOREA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 84 SOUTH KOREA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 85 SOUTH KOREA: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 86 REST OF ASIA-PACIFIC: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 87 REST OF ASIA-PACIFIC: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 88 REST OF ASIA-PACIFIC: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 89 REST OF ASIA-PACIFIC: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 90 REST OF THE WORLD: THROMBUS TREATMENT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 91 REST OF THE WORLD: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 92 REST OF THE WORLD: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030

TABLE 93 REST OF THE WORLD: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 94 REST OF THE WORLD: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 95 MIDDLE EAST: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 96 MIDDLE EAST: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030

TABLE 97 MIDDLE EAST: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 98 MIDDLE EAST: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 99 AFRICA: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 100 AFRICA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030

TABLE 101 AFRICA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 102 AFRICA: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 103 LATIN AMERICA: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 104 LATIN AMERICA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030

TABLE 105 LATIN AMERICA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 106 LATIN AMERICA: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 107 MAJOR PLAYERS IN THE GLOBAL THROMBUS TREATMENT MARKET

TABLE 108 MOST ACTIVE PLAYERS IN THE GLOBAL THROMBUS TREATMENT MARKET

TABLE 109 PRODUCT APPROVALS/PRODUCT LAUNCHES

TABLE 110 PARTNERSHIP/COLLABORATION

TABLE 111 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED

TABLE 112 TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY DEVELOPMENTS

TABLE 113 SANOFI: PRODUCTS OFFERED

TABLE 114 PFIZER INC.: PRODUCTS OFFERED

TABLE 115 BAYER AG: PRODUCTS OFFERED

TABLE 116 BAYER AG: KEY DEVELOPMENTS

TABLE 117 ANGIODYNAMICS.: PRODUCTS OFFERED

TABLE 118 ANGIODYNAMICS.: KEY DEVELOPMENTS

TABLE 119 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED

TABLE 120 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED

TABLE 121 BRISTOL-MYERS SQUIBB COMPANY: KEY DEVELOPMENTS

TABLE 122 ASPEN HOLDINGS: PRODUCTS OFFERED

TABLE 123 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED

TABLE 124 JOHNSON & JOHNSON SERVICES INC.: KEY DEVELOPMENTS

TABLE 125 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS OFFERED

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/

H&I Global Research

世界の血栓治療市場（～2030）

グローバル市場調査会社